Copyright
©The Author(s) 2015.
World J Gastroenterol. Feb 28, 2015; 21(8): 2475-2482
Published online Feb 28, 2015. doi: 10.3748/wjg.v21.i8.2475
Published online Feb 28, 2015. doi: 10.3748/wjg.v21.i8.2475
Table 1 General patient information n (%)
| Gender ratio (male:female) | 23:5 |
| Age (yr) | 25.9 ± 6.9 (13-36) |
| Mean follow-up (mo) | 26.4 (14-41) |
| Surgical history | |
| Hemorrhoidectomy | 1 (3.6) |
| Perianal abscess drainage surgery | 10 (35.7) |
| Anal fistula surgery | 15 (53.6) |
| Previous medical therapy | |
| Corticosteroids | 6 (21.4) |
| Immunomodulator therapy | 2 (7.1) |
| Infliximab | 1 (3.6) |
| No therapy | 19 (67.9) |
| Lesioned intestinal segment | |
| Ileum | 8 (28.6) |
| Colon | 4 (14.3) |
| Ileocolon | 14 (50.0) |
| Unable to assess | 2 (7.1) |
| Types of fistula | |
| Simple | 5 (17.9) |
| Complex | 23 (82.1) |
| Concomitant perianal diseases | |
| Skin tag | 4 (14.3) |
| Anal fissure | 5 (17.8) |
| Anorectal stenosis | 4 (14.3) |
| Other associated symptoms | |
| Stomach pain | 18 (64.3) |
| Diarrhea | 13 (46.4) |
| Anemia | 7 (25.0) |
| Fever | 4 (14.3) |
- Citation: Yang BL, Chen YG, Gu YF, Chen HJ, Sun GD, Zhu P, Shao WJ. Long-term outcome of infliximab combined with surgery for perianal fistulizing Crohn's disease. World J Gastroenterol 2015; 21(8): 2475-2482
- URL: https://www.wjgnet.com/1007-9327/full/v21/i8/2475.htm
- DOI: https://dx.doi.org/10.3748/wjg.v21.i8.2475